MarketCap
Facebook
X
TelegramAnnual report 2025
added 11-25-2025
Arrowhead Pharmaceuticals Operating Expenses 2011-2025 | ARWR
Annual Operating Expenses Arrowhead Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 731 M | 605 M | 446 M | 422 M | 287 M | 181 M | 108 M | 72.1 M | 68.4 M | 79.9 M | 96.4 M | 51.3 M | 23.6 M | 21.2 M | 10.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 731 M | 10.1 M | 213 M |
Quarterly Operating Expenses Arrowhead Pharmaceuticals
| 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 193 M | 164 M | - | 176 M | 126 M | 140 M | - | 119 M | 98.1 M | 105 M | - | 105 M | 110 M | 90.8 M | - | 77.8 M | 61 M | 45.4 M | 123 M | 43.3 M | 45.4 M | 34.3 M | 74 M | 24.1 M | 34.3 M | 23.7 M | 49.7 M | 16.6 M | 23.7 M | 17.3 M | 49.4 M | 15.1 M | 17.3 M | 19.3 M | 60.1 M | 19.4 M | 19.3 M | 19.4 M | 71.1 M | 16.1 M | 19.4 M | 25.3 M | 31.1 M | 12.7 M | 25.3 M | 7.05 M | 16.8 M | 6.43 M | 7.05 M | 4.97 M | 15.8 M | 6.85 M | 4.97 M | 4.06 M | 7.21 M | 1.77 M | 4.06 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 193 M | 1.77 M | 49.6 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
96.2 M | $ 4.85 | 3.03 % | $ 805 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
92.7 M | $ 3.24 | -0.46 % | $ 250 M |  USA |
 |
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
-31.8 M | $ 1.06 | -6.19 % | $ 293 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 216.6 | -1.74 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.14 | -4.56 % | $ 7.55 B |  Australia |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
BioVie
BIVI
|
18.1 M | $ 1.37 | -5.21 % | $ 2.02 M | USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
512 M | $ 93.82 | -1.04 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
168 M | $ 26.28 | 3.99 % | $ 1.27 B | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
51.6 M | $ 9.56 | - | $ 140 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 0.27 | -7.19 % | $ 588 M |  Israel |
 |
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Catalyst Biosciences
CBIO
|
176 M | $ 13.75 | -2.41 % | $ 905 M | USA |
 |
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
1.18 B | $ 545.68 | -3.3 % | $ 41.3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.37 | 3.04 % | $ 14.9 M | USA |
 |
AstraZeneca PLC
AZN
|
17.6 B | $ 91.17 | 1.49 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 8.9 | -1.22 % | $ 1.45 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.07 B | $ 11.36 | -1.52 % | $ 735 M | USA |
 |
Biogen
BIIB
|
5.39 B | $ 173.96 | -0.08 % | $ 25.3 B | USA |
 |
Abeona Therapeutics
ABEO
|
50.6 M | $ 5.09 | -5.13 % | $ 109 M | USA |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 27.29 | -0.8 % | $ 1.76 M | USA |
 |
ADiTx Therapeutics
ADTX
|
27.4 M | $ 1.65 | -26.34 % | $ 21.7 K | USA |
 |
Cellectar Biosciences
CLRB
|
15.3 M | $ 3.41 | -5.8 % | $ 41.7 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
28.5 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Завод ДИОД
DIOD
|
249 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
201 M | - | - | - | Russia |